Sensei Biotherapeutics, Inc. (SNSE)

1.7900 +0.1400 (+8.48%) 收市：04:00PM EDT

Sensei Biotherapeutics, Inc.

1405 Research Boulevard
Suite 125
Rockville, MD 20850
United States
240 243 8000
https://www.senseibio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 28

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. John K. Celebi M.B.A.	President, CEO & Director	799.69k	無	1972
Ms. Lora Pike	Vice President of Investor Relations & Communications	無	無	無
Mr. Christopher W. Gerry J.D.	Senior VP, General Counsel & Secretary	無	無	無
Dr. Aaron Weitzman FACP, M.D., Ph.D.	Chief Medical Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

公司管治

截至 2024年5月1日 止，Sensei Biotherapeutics, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：7；股東權利：10；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。